When will Alpelisib-Piqray be launched in China?

Alpelisib (Alpelisib)-PiqrayThe original drug has not yet been launched in China, and the specific launch time is not yet clear. Overseas, Apelvis was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2019. It is the first approved PI3K inhibitor for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 ( Postmenopausal women and men with HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer can be used in combination with fulvestrant, trade namePiqray, which is sold as an oral tablet. In order to initiate treatment with Apelvis, patients will need to confirm the presence of PIK3CA mutations in tissue and/or liquid biopsy sample collection with an FDA-approved diagnostic test.